Immunological and virological characteristics of human immunodeficiency virus type 1 superinfection: implications in vaccine design

doi:10.1007/s11684-017-0594-8

Frontiers of Medicine

2017, Vol. 11

Issue (4): 480-489 https://doi.org/10.1007/s11684-017-0594-8

本期目录

Immunological and virological characteristics of human immunodeficiency virus type 1 superinfection: implications in vaccine design

Yang Gao¹, Wen Tian¹, Xiaoxu Han¹(

), Feng Gao^2,³(

)

¹. Key Laboratory of AIDS Immunology of National Health and Family Planning Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University, Shenyang 110001, China
². National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China
³. Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA

全文: PDF(267 KB) HTML

Abstract：

Superinfection is frequently detected among individuals infected by human immunodeficiency virus type I (HIV-1). Superinfection occurs at similar frequencies at acute and chronic infection stages but less frequently than primary infection. This observation indicates that the immune responses elicited by natural HIV-1 infection may play a role in curb of superinfection; however, these responses are not sufficiently strong to completely prevent superinfection. Thus, a successful HIV-1 vaccine likely needs to induce more potent and broader immune responses than those elicited by primary infection. On the other hand, potent and broad neutralization responses are more often detected after superinfection than during monoinfection. This suggests that broadly neutralizing antibodies are more likely induced by sequential immunization of multiple different immunogens than with only one form of envelope glycoprotein immunogens. Understanding why the protection from superinfection by immunity induced by primary infection is insufficient and if superinfection can lead to cross-reactive immune responses will be highly informative for HIV-1 vaccine design.

Key words： human immunodeficiency virus type I superinfection incidence immune response

收稿日期: 2017-08-02 出版日期: 2017-12-04

Corresponding Author(s): Xiaoxu Han,Feng Gao

引用本文:

. [J]. Frontiers of Medicine, 2017, 11(4): 480-489.
Yang Gao, Wen Tian, Xiaoxu Han, Feng Gao. Immunological and virological characteristics of human immunodeficiency virus type 1 superinfection: implications in vaccine design. Front. Med., 2017, 11(4): 480-489.

链接本文:

https://academic.hep.com.cn/fmd/CN/10.1007/s11684-017-0594-8
https://academic.hep.com.cn/fmd/CN/Y2017/V11/I4/480

Tab.1

Tab.2

Fig.1

Fig.2

1	Allen TM, Altfeld M. HIV-1 superinfection. J Allergy Clin Immunol 2003; 112(5): 829–835, quiz 836 https://doi.org/10.1016/j.jaci.2003.08.037 pmid: 14610465
2	Smith DM, Richman DD, Little SJ. HIV superinfection. J Infect Dis 2005; 192(3): 438–444 https://doi.org/10.1086/431682 pmid: 15995957
3	Waters L, Smit E. HIV-1 superinfection. Curr Opin Infect Dis 2012; 25(1): 42–50 https://doi.org/10.1097/QCO.0b013e32834ef5af pmid: 22156898
4	Ramos A, Hu DJ, Nguyen L, Phan KO, Vanichseni S, Promadej N, Choopanya K, Callahan M, Young NL, McNicholl J, Mastro TD, Folks TM, Subbarao S. Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users. J Virol 2002; 76(15): 7444–7452 https://doi.org/10.1128/JVI.76.15.7444-7452.2002 pmid: 12097556
5	Manigart O, Courgnaud V, Sanou O, Valéa D, Nagot N, Meda N, Delaporte E, Peeters M, Van de Perre P. HIV-1 superinfections in a cohort of commercial sex workers in Burkina Faso as assessed by an autologous heteroduplex mobility procedure. AIDS 2004; 18(12): 1645–1651 https://doi.org/10.1097/01.aids.0000131333.30548.db pmid: 15280775
6	Hu DJ, Subbarao S, Vanichseni S, Mock PA, Ramos A, Nguyen L, Chaowanachan T, Griensven Fv, Choopanya K, Mastro TD, Tappero JW. Frequency of HIV-1 dual subtype infections, including intersubtype superinfections, among injection drug users in Bangkok, Thailand. AIDS 2005; 19(3): 303–308 pmid: 15718841
7	Smith DM, Strain MC, Frost SD, Pillai SK, Wong JK, Wrin T, Liu Y, Petropolous CJ, Daar ES, Little SJ, Richman DD. Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology 2006; 355(1): 1–5 https://doi.org/10.1016/j.virol.2006.08.009 pmid: 16962152
8	Redd AD, Collinson-Streng A, Martens C, Ricklefs S, Mullis CE, Manucci J, Tobian AA, Selig EJ, Laeyendecker O, Sewankambo N, Gray RH, Serwadda D, Wawer MJ, Porcella SF, Quinn TC; Rakai Health Sciences Program.Identification of HIV superinfection in seroconcordant couples in Rakai, Uganda, by use of next-generation deep sequencing. J Clin Microbiol 2011; 49(8): 2859–2867 https://doi.org/10.1128/JCM.00804-11 pmid: 21697329
9	Redd AD, Ssemwanga D, Vandepitte J, Wendel SK, Ndembi N, Bukenya J, Nakubulwa S, Grosskurth H, Parry CM, Martens C, Bruno D, Porcella SF, Quinn TC, Kaleebu P. Rates of HIV-1 superinfection and primary HIV-1 infection are similar in female sex workers in Uganda. AIDS 2014; 28(14): 2147–2152 https://doi.org/10.1097/QAD.0000000000000365 pmid: 25265078
10	Redd AD, Mullis CE, Serwadda D, Kong X, Martens C, Ricklefs SM, Tobian AA, Xiao C, Grabowski MK, Nalugoda F, Kigozi G, Laeyendecker O, Kagaayi J, Sewankambo N, Gray RH, Porcella SF, Wawer MJ, Quinn TC. The rates of HIV superinfection and primary HIV incidence in a general population in Rakai, Uganda. J Infect Dis 2012; 206(2): 267–274 https://doi.org/10.1093/infdis/jis325 pmid: 22675216
11	Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT, Montefiori DC, O’Connor DH, Davis BT, Lee PK, Maier EL, Harlow J, Goulder PJ, Brander C, Rosenberg ES, Walker BD. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 2002; 420(6914): 434–439 https://doi.org/10.1038/nature01200 pmid: 12459786
12	Basu D, Kraft CS, Murphy MK, Campbell PJ, Yu T, Hraber PT, Irene C, Pinter A, Chomba E, Mulenga J, Kilembe W, Allen SA, Derdeyn CA, Hunter E. HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection. Retrovirology 2012; 9(1): 76 https://doi.org/10.1186/1742-4690-9-76 pmid: 22995123
13	Basu D, Xiao P, Ende Z, Bere A, Britt WJ, Mulenga J, Kilembe W, Allen SA, Derdeyn CA, Hunter E. Low antibody-dependent cellular cytotoxicity responses in Zambians prior to HIV-1 intrasubtype C superinfection. Virology 2014; 462-463: 295–298 https://doi.org/10.1016/j.virol.2014.06.016 pmid: 25004405
14	Blish CA, Dogan OC, Derby NR, Nguyen MA, Chohan B, Richardson BA, Overbaugh J. Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J Virol 2008; 82(24): 12094–12103 https://doi.org/10.1128/JVI.01730-08 pmid: 18842728
15	Sun M, Zheng H, Xie Y, Li B, Long H, Guo G, Guo L, Wang J, Ning R, Li Y, Liu L. Functional effector memory T cells contribute to protection from superinfection with heterologous simian immunodeficiency virus or simian-human immunodeficiency virus isolates in Chinese rhesus macaques. Arch Virol 2017; 162(5): 1211–1221 https://doi.org/10.1007/s00705-017-3222-7 pmid: 28110425
16	Cortez V, Wang B, Dingens A, Chen MM, Ronen K, Georgiev IS, McClelland RS, Overbaugh J. The broad neutralizing antibody responses after HIV-1 superinfection are not dominated by antibodies directed to epitopes common in single infection. PLoS Pathog 2015; 11(7): e1004973 https://doi.org/10.1371/journal.ppat.1004973 pmid: 26158467
17	Powell RL, Kinge T, Nyambi PN. Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus. J Virol 2010; 84(18): 9415–9426 https://doi.org/10.1128/JVI.02732-09 pmid: 20631143
18	Cortez V, Odem-Davis K, McClelland RS, Jaoko W, Overbaugh J. HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response. PLoS Pathog 2012; 8(3): e1002611 https://doi.org/10.1371/journal.ppat.1002611 pmid: 22479183
19	Jost S, Bernard MC, Kaiser L, Yerly S, Hirschel B, Samri A, Autran B, Goh LE, Perrin L. A patient with HIV-1 superinfection. N Engl J Med 2002; 347(10): 731–736 https://doi.org/10.1056/NEJMoa020263 pmid: 12213944
20	van der Kuyl AC, Cornelissen M. Identifying HIV-1 dual infections. Retrovirology 2007; 4(1): 67 https://doi.org/10.1186/1742-4690-4-67 pmid: 17892568
21	Wagner GA, Pacold ME, Kosakovsky Pond SL, Caballero G, Chaillon A, Rudolph AE, Morris SR, Little SJ, Richman DD, Smith DM. Incidence and prevalence of intrasubtype HIV-1 dual infection in at-risk men in the United States. J Infect Dis 2014; 209(7): 1032–1038 https://doi.org/10.1093/infdis/jit633 pmid: 24273040
22	Smith DM, Wong JK, Hightower GK, Ignacio CC, Koelsch KK, Daar ES, Richman DD, Little SJ. Incidence of HIV superinfection following primary infection. JAMA 2004; 292(10): 1177–1178 https://doi.org/10.1001/jama.292.10.1177 pmid: 15353529
23	Bezemer D, van Sighem A, de Wolf F, Cornelissen M, van der Kuyl AC, Jurriaans S, van der Hoek L, Prins M, Coutinho RA, Lukashov VV. Combination antiretroviral therapy failure and HIV super-infection. AIDS 2008; 22(2): 309–311 https://doi.org/10.1097/QAD.0b013e3282f37489 pmid: 18097235
24	Sidat MM, Mijch AM, Lewin SR, Hoy JF, Hocking J, Fairley CK. Incidence of putative HIV superinfection and sexual practices among HIV-infected men who have sex with men. Sex Health 2008; 5(1): 61–67 https://doi.org/10.1071/SH07041 pmid: 18361856
25	Wagner GA, Pacold ME, Vigil E, Caballero G, Morris SR, Kosakovsky Pond SL, Little SJ, Richman DD, Gianella S, Smith DM. Using ultradeep pyrosequencing to study HIV-1 coreceptor usage in primary and dual infection. J Infect Dis 2013; 208(2): 271–274 https://doi.org/10.1093/infdis/jit168 pmid: 23599311
26	Promadej-Lanier N, Thielen C, Hu DJ, Chaowanachan T, Gvetadze R, Choopanya K, Vanichseni S, McNicholl JM. Cross-reactive T cell responses in HIV CRF01_AE and B′-infected intravenous drug users: implications for superinfection and vaccines. AIDS Res Hum Retroviruses 2009; 25(1): 73–81 https://doi.org/10.1089/aid.2008.0169 pmid: 19182923
27	McCutchan FE, Hoelscher M, Tovanabutra S, Piyasirisilp S, Sanders-Buell E, Ramos G, Jagodzinski L, Polonis V, Maboko L, Mmbando D, Hoffmann O, Riedner G, von Sonnenburg F, Robb M, Birx DL. In-depth analysis of a heterosexually acquired human immunodeficiency virus type 1 superinfection: evolution, temporal fluctuation, and intercompartment dynamics from the seronegative window period through 30 months postinfection. J Virol 2005; 79(18): 11693–11704 https://doi.org/10.1128/JVI.79.18.11693-11704.2005 pmid: 16140747
28	Redd AD, Mullis CE, Wendel SK, Sheward D, Martens C, Bruno D, Werner L, Garrett NJ, Abdool Karim Q, Williamson C, Porcella SF, Quinn TC, Abdool Karim SS. Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial. J Clin Microbiol 2014; 52(3): 844–848 https://doi.org/10.1128/JCM.03143-13 pmid: 24371237
29	Grobler J, Gray CM, Rademeyer C, Seoighe C, Ramjee G, Karim SA, Morris L, Williamson C. Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis 2004; 190(7): 1355–1359 https://doi.org/10.1086/423940 pmid: 15346349
30	Redd AD, Wendel SK, Longosz AF, Fogel JM, Dadabhai S, Kumwenda N, Sun J, Walker MP, Bruno D, Martens C, Eshleman SH, Porcella SF, Quinn TC, Taha TE. Evaluation of postpartum HIV superinfection and mother-to-child transmission. AIDS 2015; 29(12): 1567–1573 https://doi.org/10.1097/QAD.0000000000000740 pmid: 26244396
31	Chohan B, Lavreys L, Rainwater SM, Overbaugh J. Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. J Virol 2005; 79(16): 10701–10708 https://doi.org/10.1128/JVI.79.16.10701-10708.2005 pmid: 16051862
32	Redd AD, Quinn TC, Tobian AA. Frequency and implications of HIV superinfection. Lancet Infect Dis 2013; 13(7): 622–628 https://doi.org/10.1016/S1473-3099(13)70066-5 pmid: 23726798
33	Gottlieb GS, Nickle DC, Jensen MA, Wong KG, Grobler J, Li F, Liu SL, Rademeyer C, Learn GH, Karim SS, Williamson C, Corey L, Margolick JB, Mullins JI. Dual HIV-1 infection associated with rapid disease progression. Lancet 2004; 363(9409): 619–622 https://doi.org/10.1016/S0140-6736(04)15596-7 pmid: 14987889
34	Tsui R, Herring BL, Barbour JD, Grant RM, Bacchetti P, Kral A, Edlin BR, Delwart EL. Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. J Virol 2004; 78(1): 94–103 https://doi.org/10.1128/JVI.78.1.94-103.2004 pmid: 14671091
35	Rachinger A, Stolte IG, van de Ven TD, Burger JA, Prins M, Schuitemaker H, van’t Wout AB. Absence of HIV-1 superinfection 1 year after infection between 1985 and 1997 coincides with a reduction in sexual risk behavior in the seroincident Amsterdam cohort of homosexual men. Clin Infect Dis 2010; 50(9): 1309–1315 https://doi.org/10.1086/651687 pmid: 20367230
36	Rachinger A, van de Ven TD, Burger JA, Schuitemaker H, van’t Wout AB. Evaluation of pre-screening methods for the identification of HIV-1 superinfection. J Virol Methods 2010; 165(2): 311–317 https://doi.org/10.1016/j.jviromet.2010.02.016 pmid: 20178816
37	Rachinger A, Manyenga P, Burger JA, Derks van de Ven TL, Stolte IG, Prins M, van’t Wout AB, Schuitemaker H. Low incidence of HIV-1 superinfection even after episodes of unsafe sexual behavior of homosexual men in the Amsterdam Cohort Studies on HIV Infection and AIDS. J Infect Dis 2011; 203(11): 1621–1628 https://doi.org/10.1093/infdis/jir164 pmid: 21592992
38	Templeton AR, Kramer MG, Jarvis J, Kowalski J, Gange S, Schneider MF, Shao Q, Zhang GW, Yeh MF, Tsai HL, Zhang H, Markham RB. Multiple-infection and recombination in HIV-1 within a longitudinal cohort of women. Retrovirology 2009; 6(1): 54 https://doi.org/10.1186/1742-4690-6-54 pmid: 19493346
39	Koelsch KK, Smith DM, Little SJ, Ignacio CC, Macaranas TR, Brown AJ, Petropoulos CJ, Richman DD, Wong JK. Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus. AIDS 2003; 17(7): F11–F16 https://doi.org/10.1097/00002030-200305020-00001 pmid: 12700477
40	Piantadosi A, Chohan B, Chohan V, McClelland RS, Overbaugh J. Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog 2007; 3(11): e177 https://doi.org/10.1371/journal.ppat.0030177 pmid: 18020705
41	Piantadosi A, Ngayo MO, Chohan B, Overbaugh J. Examination of a second region of the HIV type 1 genome reveals additional cases of superinfection. AIDS Res Hum Retroviruses 2008; 24(9): 1221–1224 https://doi.org/10.1089/aid.2008.0100 pmid: 18729772
42	Kraft CS, Basu D, Hawkins PA, Hraber PT, Chomba E, Mulenga J, Kilembe W, Khu NH, Derdeyn CA, Allen SA, Manigart O, Hunter E. Timing and source of subtype-C HIV-1 superinfection in the newly infected partner of Zambian couples with disparate viruses. Retrovirology 2012; 9(1): 22 https://doi.org/10.1186/1742-4690-9-22 pmid: 22433432
43	Sheward DJ, Ntale R, Garrett NJ, Woodman ZL, Abdool Karim SS, Williamson C. HIV-1 superinfection resembles primary infection. J Infect Dis 2015; 212(6): 904–908 https://doi.org/10.1093/infdis/jiv136 pmid: 25754982
44	Shapland EB, Holmes V, Reeves CD, Sorokin E, Durot M, Platt D, Allen C, Dean J, Serber Z, Newman J, Chandran S. Low-cost, high-throughput sequencing of DNA assemblies using a highly multiplexed nextera process. ACS Synth Biol 2015; 4(7): 860–866 https://doi.org/10.1021/sb500362n pmid: 25913499
45	Mild M, Hedskog C, Jernberg J, Albert J. Performance of ultra-deep pyrosequencing in analysis of HIV-1 pol gene variation. PLoS One 2011; 6(7): e22741 https://doi.org/10.1371/journal.pone.0022741 pmid: 21799940
46	Kijak GH, Sanders-Buell E, Harbolick EA, Pham P, Chenine AL, Eller LA, Rono K, Robb ML, Michael NL, Kim JH, Tovanabutra S. Targeted deep sequencing of HIV-1 using the IonTorrentPGM platform. J Virol Methods 2014; 205: 7–16 https://doi.org/10.1016/j.jviromet.2014.04.017 pmid: 24797459
47	Ronen K, McCoy CO, Matsen FA, Boyd DF, Emery S, Odem-Davis K, Jaoko W, Mandaliya K, McClelland RS, Richardson BA, Overbaugh J. HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women. PLoS Pathog 2013; 9(8): e1003593 https://doi.org/10.1371/journal.ppat.1003593 pmid: 24009513
48	Luan H, Han X, Yu X, An M, Zhang H, Zhao B, Xu J, Chu Z, Shang H. Dual infection contributes to rapid disease progression in men who have sex with men in China. J Acquir Immune Defic Syndr 2017; 75(4): 480–487 https://doi.org/10.1097/QAI.0000000000001420 pmid: 28490044
49	Soares de Oliveira AC, Pessôa de Farias R, da Costa AC, Sauer MM, Bassichetto KC, Oliveira SM, Costa PR, Tomiyama C, Tomiyama HT, Sabino EC, Kallas EG, Sanabani SS. Frequency of subtype B and F1 dual infection in HIV-1 positive, Brazilian men who have sex with men. Virol J 2012; 9(1): 223 https://doi.org/10.1186/1743-422X-9-223 pmid: 23021203
50	Chohan BH, Piantadosi A, Overbaugh J. HIV-1 superinfection and its implications for vaccine design. Curr HIV Res 2010; 8(8): 596–601 https://doi.org/10.2174/157016210794088218 pmid: 21054252
51	Yerly S, Jost S, Monnat M, Telenti A, Cavassini M, Chave JP, Kaiser L, Burgisser P, Perrin L; Swiss HIV Cohort Study. HIV-1 co/super-infection in intravenous drug users. AIDS 2004; 18(10): 1413–1421 https://doi.org/10.1097/01.aids.0000131330.28762.0c pmid: 15199317
52	Courtney CR, Mayr L, Nanfack AJ, Banin AN, Tuen M, Pan R, Jiang X, Kong XP, Kirkpatrick AR, Bruno D, Martens CA, Sykora L, Porcella SF, Redd AD, Quinn TC, Nyambi PN, Dürr R. Contrasting antibody responses to intrasubtype superinfection with CRF02_AG. PLoS One 2017; 12(3): e0173705 https://doi.org/10.1371/journal.pone.0173705 pmid: 28288209
53	Ritchie AJ, Cai F, Smith NM, Chen S, Song H, BrackenridgeS, Abdool KarimSS, KorberBT, McMichaelAJ, GaoF, GoonetellekeN. Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection. Retrovirology2014; 11: 69 https://doi.org/10.1186/s12977-014-0069-9 pmid: 25212771
54	Streeck H, Li B, Poon AF, Schneidewind A, Gladden AD, Power KA, Daskalakis D, Bazner S, Zuniga R, Brander C, Rosenberg ES, Frost SD, Altfeld M, Allen TM. Immune-driven recombination and loss of control after HIV superinfection. J Exp Med 2008; 205(8): 1789–1796 https://doi.org/10.1084/jem.20080281 pmid: 18625749
55	Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O’Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z; NISC Comparative Sequencing Program, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014; 509(7498): 55–62 https://doi.org/10.1038/nature13036 pmid: 24590074
56	Diaz RS, Pardini R, Catroxo M, Operskalski EA, Mosley JW, Busch MP. HIV-1 superinfection is not a common event. J Clin Virol 2005; 33(4): 328–330 https://doi.org/10.1016/j.jcv.2004.11.021 pmid: 16036183
57	Chakraborty B, Valer L, De Mendoza C, Soriano V, Quiñones-Mateu ME. Failure to detect human immunodeficiency virus type 1 superinfection in 28 HIV-seroconcordant individuals with high risk of reexposure to the virus. AIDS Res Hum Retroviruses 2004; 20(9): 1026–1031 https://doi.org/10.1089/aid.2004.20.1026 pmid: 15585092
58	Gonzales MJ, Delwart E, Rhee SY, Tsui R, Zolopa AR, Taylor J, Shafer RW. Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. J Infect Dis 2003; 188(3): 397–405 https://doi.org/10.1086/376534 pmid: 12870121
59	Martin F, Lee J, Thomson E, Tarrant N, Hale A, Lacey CJ. Two cases of possible transmitted drug-resistant HIV: likely HIV superinfection and unmasking of pre-existing resistance. Int J STD AIDS 2016; 27(1): 66–69 https://doi.org/10.1177/0956462415571671 pmid: 25663247
60	Cowan SA, Gerstoft J, Haff J, Christiansen AH, Nielsen J, Obel N. Stable incidence of HIV diagnoses among Danish MSM despite increased engagement in unsafe sex. J Acquir Immune Defic Syndr 2012; 61(1): 106–111 https://doi.org/10.1097/QAI.0b013e31825af890 pmid: 22592584
61	Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Günthard HF. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11(6): 615–622 https://doi.org/10.1038/nm1244 pmid: 15880120
62	Mehandru S, Vcelar B, Wrin T, Stiegler G, Joos B, Mohri H, Boden D, Galovich J, Tenner-Racz K, Racz P, Carrington M, Petropoulos C, Katinger H, Markowitz M. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol 2007; 81(20): 11016–11031 https://doi.org/10.1128/JVI.01340-07 pmid: 17686878
63	Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S, Nkolola JP, Seaman MS, Smith KM, Borducchi EN, Cabral C, Smith JY, Blackmore S, Sanisetty S, Perry JR, Beck M, Lewis MG, Rinaldi W, Chakraborty AK, Poignard P, Nussenzweig MC, Burton DR. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503(7475): 224–228 pmid: 24172905
64	Wagner GA, Landais E, Caballero G, Phung P, Kosakovsky Pond SL, Poignard P, Richman DD, Little SJ, Smith DM. Intrasubtype B HIV-1 superinfection correlates with delayed neutralizing antibody response. J Virol 2017; 91(17): e00475-17 https://doi.org/10.1128/JVI.00475-17 pmid: 28615205
65	Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 2011; 7(1): e1001251 https://doi.org/10.1371/journal.ppat.1001251 pmid: 21249232
66	Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, Morris L; CAPRISA 002 Study. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol 2011; 85(7): 3128–3141 https://doi.org/10.1128/JVI.02658-10 pmid: 21270156
53	Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, Fire AZ, Roskin KM, Schramm CA, Zhang Z, Zhu J, Shapiro L; NISC Comparative Sequencing Program, Mullikin JC, Gnanakaran S, Hraber P, Wiehe K, Kelsoe G, Yang G, Xia SM, Montefiori DC, Parks R, Lloyd KE, Scearce RM, Soderberg KA, Cohen M, Kamanga G, Louder MK, Tran LM, Chen Y, Cai F, Chen S, Moquin S, Du X, Joyce MG, Srivatsan S, Zhang B, Zheng A, Shaw GM, Hahn BH, Kepler TB, Korber BT, Kwong PD, Mascola JR, Haynes BF. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013; 496(7446): 469–476 https://doi.org/10.1038/nature12053 pmid: 23552890
67	Weinfurter JT, May GE, Soma T, Hessell AJ, León EJ, Macnair CE, Piaskowski SM, Weisgrau K, Furlott J, Maness NJ, Reed J, Wilson NA, Rakasz EG, Burton DR, Friedrich TC. Macaque long-term nonprogressors resist superinfection with multiple CD8+ T cell escape variants of simian immunodeficiency virus. J Virol 2011; 85(1): 530–541 https://doi.org/10.1128/JVI.01025-10 pmid: 20962091
68	Blish CA, Dogan OC, Jaoko W, McClelland RS, Mandaliya K, Odem-Davis KS, Richardsonb BA, Overbaugh J. Cellular immune responses and susceptibility to HIV-1 superinfection: a case-control study. AIDS 2012; 26(5): 643–646 https://doi.org/10.1097/QAD.0b013e3283509a0b pmid: 22210637
69	Forthal DN, Landucci G, Chohan B, Richardson BA, McClelland RS, Jaoko W, Blish C, Overbaugh J. Antibody-dependent cell-mediated virus inhibition antibody activity does not correlate with risk of HIV-1 superinfection. J Acquir Immune Defic Syndr 2013; 63(1): 31–33 https://doi.org/10.1097/QAI.0b013e3182874d41 pmid: 23344546
70	Blish CA, Dogan OC, Jaoko W, McClelland RS, Mandaliya K, Odem-Davis K, Richardson BA, Overbaugh J. Association between cellular immune activation, target cell frequency, and risk of human immunodeficiency virus type 1 superinfection. J Virol 2014; 88(10): 5894–5899 https://doi.org/10.1128/JVI.00187-14 pmid: 24623424
71	Ronen K, Dingens AS, Graham SM, Jaoko W, Mandaliya K, McClelland RS, Overbaugh J. Comprehensive characterization of humoral correlates of human immunodeficiency virus 1 superinfection acquisition in high-risk Kenyan women. EBioMedicine 2017; 18: 216–224 https://doi.org/10.1016/j.ebiom.2017.04.005 pmid: 28427948
72	Vesa J, Chaillon A, Wagner GA, Anderson CM, Richman DD, Smith DM, Little SJ. Increased HIV-1 superinfection risk in carriers of specific human leukocyte antigen alleles. AIDS 2017; 31(8): 1149–1158 https://doi.org/10.1097/QAD.0000000000001445 pmid: 28244954
73	Campbell MS, Gottlieb GS, Hawes SE, Nickle DC, Wong KG, Deng W, Lampinen TM, Kiviat NB, Mullins JI. HIV-1 superinfection in the antiretroviral therapy era: are seroconcordant sexual partners at risk? PLoS One 2009; 4(5): e5690 https://doi.org/10.1371/journal.pone.0005690 pmid: 19479055
74	Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012; 30(5):423–433 https://doi.org/10.1038/nbt.2197 pmid: 22565972
75	Haynes BF, Shaw GM, Korber B, Kelsoe G, Sodroski J, Hahn BH, Borrow P, McMichael AJ. HIV-host interactions: implications for vaccine design. Cell Host Microbe 2016; 19:292–303 https://doi.org/10.1016/j.chom.2016.02.002 pmid: 26922989
76	Gao F. Broad neutralization as a byproduct of antibody maturation during HIV-1 infection: a personal perspective. Infect Dis Transl Med 2016; 2:60–68
77	Piantadosi A, Panteleeff D, Blish CA, Baeten JM, Jaoko W, McClelland RS, Overbaugh J. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol 2009; 83(19): 10269–10274 https://doi.org/10.1128/JVI.01149-09 pmid: 19640996
78	Euler Z, van den Kerkhof TL, van Gils MJ, Burger JA, Edo-Matas D, Phung P, Wrin T, Schuitemaker H. Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. J Virol 2012; 86(4): 2045–2055 https://doi.org/10.1128/JVI.06091-11 pmid: 22156522
79	Pernas M, Casado C, Arcones C, Llano A, Sánchez-Merino V, Mothe B, Vicario JL, Grau E, Ruiz L, Sánchez J, Telenti A, Yuste E, Brander C, Galíndez CL. Low-replicating viruses and strong anti-viral immune response associated with prolonged disease control in a superinfected HIV-1 LTNP elite controller. PLoS One 2012; 7(2): e31928 https://doi.org/10.1371/journal.pone.0031928 pmid: 22384103

Viewed

Full text

Abstract

Cited

Shared

Discussed